Sebaceous carcinoma of the eyelid in a patient with Muir-Torre syndrome treated with pembrolizumab: A case report

Dasgupta, 2009, A retrospective review of 1349 cases of sebaceous carcinoma, Cancer, 115, 158, 10.1002/cncr.23952 Mahalingam, 2017, MSH6, past and present and Muir–Torre syndrome—connecting the dots, Am. J. Dermatopathol., 39, 239, 10.1097/DAD.0000000000000633 Ponti, 2005, Muir-Torre syndrome, Lancet Oncol., 6, 980, 10.1016/S1470-2045(05)70465-4 Kyllo, 2015, Sebaceous carcinoma: review of the literature, Dermatol. Surg., 41, 1, 10.1097/DSS.0000000000000152 Kopsidas, 2020, Concomitant orbital tumours: small lymphocytic lymphoma involving the lacrimal gland of a patient with clinical diagnoses of Muir-Torre syndrome and extensive sebaceous gland carcinoma of the ipsilateral eyelid, Ocul. Oncol. Pathol., 6, 15, 10.1159/000500161 Tanyi, 2009, A new mutation in Muir-Torre syndrome associated with familiar transmission of different gastrointestinal adenocarcinomas, Eur. J. Surg. Oncol. (EJSO), 35, 1128, 10.1016/j.ejso.2009.03.011 Vernez, 2007, A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene, Fam. Cancer, 6, 141, 10.1007/s10689-006-9105-9 Tailor, 2012, Acute myeloid leukaemia associated with Muir-Torre variant of hereditary non-polyposis colon cancer (HNPCC): implications for inherited and acquired mutations in DNA mismatch repair genes, Br. J. Haematol., 156, 289, 10.1111/j.1365-2141.2011.08862.x Kamisasanuki, 2013, A case of Muir-Torre syndrome with multiple cancers of bilateral eyelids and breast, Korean J. Ophthalmol., 27, 204, 10.3341/kjo.2013.27.3.204 Nolan, 2009, First case report of Muir–Torre syndrome associated with non-small cell lung cancer, Fam. Cancer, 8, 359, 10.1007/s10689-009-9247-7 Cohen, 1992, Muir-Torre syndrome in patients with hematologic malignancies, Am. J. Hematol., 40, 64, 10.1002/ajh.2830400114 Wong, 2015, Muir-Torre syndrome in a middle-aged chinese patient with sebaceous carcinoma of the eyelid, Semin. Ophthalmol., 30, 420, 10.3109/08820538.2013.833267 Le, 2020, Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164, J. Clin. Oncol., 38, 11, 10.1200/JCO.19.02107 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 US Food and Drug Administration press release. FDA approves first cancer treatment for any solid tumour with a specific genetic feature.https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm560167.htm (Accessed on July 28, 2021). Tetzlaff, 2016, Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma, J. Pathol., 240, 84, 10.1002/path.4759 North, 2018, Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma, Nat. Commun., 9, 1, 10.1038/s41467-018-04008-y Domingo-Musibay, 2018, Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma, J. Immunother. Cancer, 6, 1, 10.1186/s40425-018-0357-3